CVS Health Corp is a diversified healthcare company that operates a vast network of retail pharmacies, providing prescription medications, over-the-counter products, and health and wellness services. In addition to its retail operations, CVS Health also offers pharmacy benefit management services, helping manage prescription drug costs for businesses and health plans. The company is involved in providing health insurance and health services through its various divisions, including a growing presence in digital health solutions and immunization services. By integrating pharmacy services with healthcare delivery, CVS Health aims to enhance patient care and improve health outcomes across the communities it serves. Read More
Despite a broad market correction in 2025, three S&P 500 stocks have defied the downturn, delivering standout performance and showcasing strong fundamentals.
Stay informed about the performance of the S&P500 index in the middle of the day on Tuesday. Uncover the top gainers and losers in today's session for valuable insights.
U.S. stocks staged a broad-based rally on Monday, snapping a volatile losing streak after President Donald Trump hinted at a more diplomatic approach to tariff negotiations.
Wondering what's happening in today's session regarding gap up and gap down stocks? Explore the S&P500 index on Tuesday to uncover the stocks that are gapping in the S&P500 index.
CVS Health is one of the largest healthcare companies in the United States, integrating pharmacy services, benefit management, and retail healthcare delivery.
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the S&P500 top gainers and losers.
U.S. stocks surge after Trump hints at trade progress, easing fears of disruption. S&P 500 up 3%, tech-heavy Nasdaq 100 outperforms. Semiconductors lead sector rally.
Health insurer stocks are trading higher after the market close on Monday following a report indicating the Trump administration will increase payment rates for Medicare insurers.
The FTC has paused its antitrust case against major PBMs, citing a lack of commissioners. The lawsuit alleges unfair practices that inflated insulin prices.
